Marc Semigran - 24 Dec 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role
Chief Development Officer
Signature
/s/ John R. Moore, Attorney-in-Fact for Semigran Marc
Issuer symbol
EWTX
Transactions as of
24 Dec 2024
Net transactions value
-$616,317
Form type
4
Filing time
27 Dec 2024, 16:30:04 UTC
Previous filing
14 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EWTX Common Stock Options Exercise $265,598 +29,709 +442% $8.94 36,425 24 Dec 2024 Direct F1
transaction EWTX Common Stock Sale $829,906 -27,980 -77% $29.66 8,445 24 Dec 2024 Direct F2, F3
transaction EWTX Common Stock Sale $52,009 -1,729 -20% $30.08 6,716 24 Dec 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EWTX Stock Option (Right to Buy) Options Exercise $0 -29,709 -9.9% $0.000000 270,291 24 Dec 2024 Common Stock 29,709 $8.94 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 2,187 shares purchased on November 15, 2023, 2,254 shares purchased on May 15, 2024 and 2,275 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2024.
F3 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.03 to $30.02, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 1/4th of the shares subject to the option became vested and exercisable on December 19, 2023 and 1/48th of the shares subject to the option continue to vest each month thereafter, subject to the Reporting Person continuing as a service provider through each vest date.